Report from the 12th Retrovirus Conference
Report from the 12th Retrovirus Conference
This year's Retrovirus Conference returned to Boston, and despite predictably wintry weather, the premier scientific HIV meeting again attracted researchers and clinicians from all over the world. Indeed, the conference continued its string of "sold out" engagements: With registration limited to 3500, many who missed the deadline were sorely disappointed.
As always, the conference offered a wide range of both basic and clinical research, and we at ACC have chosen the oral and poster presentations that we believe have the greatest relevance to clinical care. Of particular interest this year were several studies revealing a suddenly full drug-development pipeline, numerous updates on antiretroviral rollout efforts in the developing world, further discussion of the role of nevirapine for prevention of perinatal transmission, several "switch" studies showing improvement in lipoatrophy, and a more complete description of the now infamous New York patient who presented with multidrug-resistant virus and rapid disease progression (see ACC March 2005, p. 21). All abstracts, along with webcasts of symposia sessions, are available at the meeting website: www.retroconference.org . -- Paul E. Sax, MD
This year's Retrovirus Conference returned to Boston, and despite predictably wintry weather, the premier scientific HIV meeting again attracted researchers and clinicians from all over the world. Indeed, the conference continued its string of "sold out" engagements: With registration limited to 3500, many who missed the deadline were sorely disappointed.
As always, the conference offered a wide range of both basic and clinical research, and we at ACC have chosen the oral and poster presentations that we believe have the greatest relevance to clinical care. Of particular interest this year were several studies revealing a suddenly full drug-development pipeline, numerous updates on antiretroviral rollout efforts in the developing world, further discussion of the role of nevirapine for prevention of perinatal transmission, several "switch" studies showing improvement in lipoatrophy, and a more complete description of the now infamous New York patient who presented with multidrug-resistant virus and rapid disease progression (see ACC March 2005, p. 21). All abstracts, along with webcasts of symposia sessions, are available at the meeting website: www.retroconference.org . -- Paul E. Sax, MD
Source...